Multiple Sclerosis Disease Breakthrough on B-cell Depleting Therapies: Experience of a Tertiary Academic Medical Center in the Midwest (P9-6.016)

To review patients with relapsing forms of multiple sclerosis (MS) who had a clinical or/and radiologic relapse while on a B cell therapy (rituximab, ocrelizumab, or ofatumumab) with low (CD19 <15) or suppressed (CD19 of 0) B cells, with a few exceptions, evaluating for any commonalities or extenuating circumstances leading to relapse.